Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FL-101 Neoadjuvant Therapy in Resectable NSCLC
NCT04758949Phase 2Withdrawn
- Sponsor
- Flame Biosciences
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of abdakibart in non-small cell lung cancer (NSCLC), sponsored by Flame Biosciences. Planned start Aug 2021; status: withdrawn.
02
Drugs
abdakibart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04758949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04758949.